Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non‐Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study

Adding ICI to platinum retreatment may be an effective option for patients with NSCLC who relapse after perioperative chemotherapy, particularly in those with PD-L1 expression ≥ 50%.